MCID: PRM013
MIFTS: 44

Premature Menopause

Categories: Endocrine diseases, Reproductive diseases

Aliases & Classifications for Premature Menopause

MalaCards integrated aliases for Premature Menopause:

Name: Premature Menopause 12 15 73
Menopause - Premature 12
Menopause, Premature 44
Menopause Premature 55
Menopause Praecox 12

Classifications:



External Ids:

Disease Ontology 12 DOID:10787
ICD10 33 E28.31 E28.319
ICD9CM 35 256.31
MeSH 44 D008594
NCIt 50 C80099
SNOMED-CT 68 74296006
UMLS 73 C0025322

Summaries for Premature Menopause

Disease Ontology : 12 An ovarian dysfunction that is the loss of normal ovarian function before age 40.

MalaCards based summary : Premature Menopause, also known as menopause - premature, is related to premature ovarian failure 1 and alpha/beta t-cell lymphopenia with gamma/delta t-cell expansion, severe cytomegalovirus infection, and autoimmunity. An important gene associated with Premature Menopause is BRCA1 (BRCA1, DNA Repair Associated), and among its related pathways/superpathways are DNA Damage and Meiosis. The drugs Lenograstim and Estradiol have been mentioned in the context of this disorder. Affiliated tissues include bone, ovary and testes, and related phenotypes are Decreased viability with cisplatin and Synthetic lethal with cisplatin

Related Diseases for Premature Menopause

Diseases related to Premature Menopause via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 89)
# Related Disease Score Top Affiliating Genes
1 premature ovarian failure 1 32.5 SYCE1 SGO2 GNRH1 AMH
2 alpha/beta t-cell lymphopenia with gamma/delta t-cell expansion, severe cytomegalovirus infection, and autoimmunity 30.0 TPO TG
3 polyneuropathy-intellectual disability-acromicria-premature menopause syndrome 12.5
4 breast cancer 10.2
5 hereditary site-specific ovarian cancer syndrome 10.2 BRCA2 BRCA1
6 cancerophobia 10.2 BRCA2 BRCA1
7 nosophobia 10.2 BRCA2 BRCA1
8 tuberculous salpingitis 10.2 BRCA2 BRCA1
9 breast reconstruction 10.2 BRCA2 BRCA1
10 breast-ovarian cancer, familial 1 10.2 BRCA2 BRCA1
11 fallopian tube adenocarcinoma 10.2 BRCA2 BRCA1
12 synchronous bilateral breast carcinoma 10.2 BRCA2 BRCA1
13 glycogen-rich clear cell breast carcinoma 10.2 BRCA2 BRCA1
14 peritoneum cancer 10.2 BRCA2 BRCA1
15 fallopian tube disease 10.2 BRCA2 BRCA1
16 primary peritoneal carcinoma 10.2 BRCA2 BRCA1
17 bilateral breast cancer 10.2 BRCA2 BRCA1
18 fanconi anemia, complementation group q 10.2 BRCA2 BRCA1
19 mutagen sensitivity 10.2 BRCA2 BRCA1
20 lynch syndrome i 10.2 BRCA2 BRCA1
21 pre-malignant neoplasm 10.2 BRCA2 BRCA1
22 dysgerminoma of ovary 10.2 BRCA2 BRCA1
23 fallopian tube carcinoma 10.2 BRCA2 BRCA1
24 breast carcinoma in situ 10.2 BRCA2 BRCA1
25 ovarian cancer 1 10.2 BRCA2 BRCA1
26 malignant ovarian surface epithelial-stromal neoplasm 10.1 BRCA1 BRCA2
27 ovary epithelial cancer 10.1 BRCA1 BRCA2
28 subacute lymphocytic thyroiditis 10.1 TPO TG
29 thyroiditis 10.1 TG TPO
30 cystadenofibroma 10.1 TG BRCA2
31 female breast cancer 10.1 BRCA1 BRCA2
32 familial thyroid dyshormonogenesis 10.1 TPO TG
33 neonatal hypothyroidism 10.1 TPO TG
34 goiter, multinodular 1, with or without sertoli-leydig cell tumors 10.1 TPO TG
35 endemic goiter 10.1 TPO TG
36 plummer's disease 10.1 TPO TG
37 nontoxic goiter 10.1 TPO TG
38 graves disease 1 10.1 TPO TG
39 subacute thyroiditis 10.1 TPO TG
40 toxic diffuse goiter 10.1 TPO TG
41 myxedema 10.1 TPO TG
42 pernicious anemia 10.1 TPO TG
43 hypothyroidism, thyroidal or athyroidal, with spiky hair and cleft palate 10.1 TPO TG
44 hypothyroidism, congenital, nongoitrous, 4 10.1 TPO TG
45 nodular goiter 10.1 TPO TG
46 lymphoma 10.1
47 autoimmune disease of endocrine system 10.1 TPO TG
48 sporadic breast cancer 10.1 BRCA1 BRCA2
49 ductal carcinoma in situ 10.1 BRCA1 BRCA2
50 multinodular goiter 10.1 TG TPO

Graphical network of the top 20 diseases related to Premature Menopause:



Diseases related to Premature Menopause

Symptoms & Phenotypes for Premature Menopause

GenomeRNAi Phenotypes related to Premature Menopause according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability with cisplatin GR00101-A-4 8.96 BRCA1 BRCA2
2 Synthetic lethal with cisplatin GR00101-A-1 8.62 BRCA1 BRCA2

MGI Mouse Phenotypes related to Premature Menopause:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 endocrine/exocrine gland MP:0005379 9.92 AMH BRCA1 BRCA2 GNRH1 POLG SYCE1
2 homeostasis/metabolism MP:0005376 9.86 AMH BRCA1 BRCA2 GNRH1 POLG SYCE1
3 digestive/alimentary MP:0005381 9.77 BRCA1 BRCA2 GNRH1 POLG TG
4 neoplasm MP:0002006 9.55 AMH BRCA1 BRCA2 GNRH1 POLG
5 reproductive system MP:0005389 9.43 AMH BRCA1 BRCA2 GNRH1 POLG SYCE1
6 skeleton MP:0005390 9.1 BRCA1 BRCA2 GNRH1 POLG TG TPO

Drugs & Therapeutics for Premature Menopause

Drugs for Premature Menopause (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 191)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Lenograstim Approved, Investigational Phase 4 135968-09-1
2
Estradiol Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 50-28-2 5757
3
Polyestradiol phosphate Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 28014-46-2
4 Estradiol valerate Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 979-32-8
5
Ethinyl Estradiol Approved Phase 4,Phase 3,Phase 2,Not Applicable 57-63-6 5991
6
Progesterone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Not Applicable,Early Phase 1 57-83-0 5994
7
Norethindrone Approved Phase 4,Phase 2,Phase 3,Not Applicable 68-22-4 6230
8
Ganirelix Approved Phase 4 123246-29-7, 124904-93-4 25081094
9
Leuprolide Approved, Investigational Phase 4,Phase 2 53714-56-0 657181 3911
10
Dopamine Approved Phase 4,Not Applicable 51-61-6, 62-31-7 681
11
Vitamin C Approved, Nutraceutical Phase 4 50-81-7 5785 54670067
12
Lactitol Investigational Phase 4 585-86-4 3871
13 Deslorelin Investigational, Vet_approved Phase 4,Phase 2,Phase 3 57773-65-6
14 Immunologic Factors Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
15 Adjuvants, Immunologic Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1
16 Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
17 Estradiol 3-benzoate Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
18 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
19 Hormones Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
20 Estrogens Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
21 Estradiol 17 beta-cypionate Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
22 Progestins Phase 4,Phase 3,Phase 2,Not Applicable,Early Phase 1
23 Contraceptive Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
24 Norinyl Phase 4
25 Contraceptives, Oral Phase 4,Phase 2,Phase 3,Not Applicable
26 Norethindrone acetate Phase 4,Phase 2,Phase 3,Not Applicable
27 Norethindrone acetate, ethinyl estradiol, ferrous fumarate drug combination Phase 4
28 Antineoplastic Agents, Hormonal Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
29 Triptorelin Pamoate Phase 4,Phase 3,Phase 2,Not Applicable
30 Luteolytic Agents Phase 4,Phase 3,Phase 2,Not Applicable
31 Neurotransmitter Agents Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable
32 Neurotransmitter Uptake Inhibitors Phase 4,Not Applicable
33 Dopamine Agents Phase 4,Not Applicable
34 Dopamine Uptake Inhibitors Phase 4,Not Applicable
35 Central Nervous System Stimulants Phase 4,Phase 1,Phase 2,Not Applicable
36 Lisdexamfetamine Dimesylate Phase 4,Not Applicable
37
Cyclophosphamide Approved, Investigational Phase 3,Phase 2 6055-19-2, 50-18-0 2907
38
Goserelin Approved Phase 3,Phase 2 65807-02-5 47725 5311128
39
Docetaxel Approved, Investigational Phase 3 114977-28-5 148124
40
Epirubicin Approved Phase 3 56420-45-2 41867
41
leucovorin Approved Phase 3 58-05-9 6006 143
42
Paclitaxel Approved, Vet_approved Phase 3 33069-62-4 36314
43
Methotrexate Approved Phase 3 59-05-2, 1959-05-2 126941
44
Fluorouracil Approved Phase 3 51-21-8 3385
45
Doxorubicin Approved, Investigational Phase 3 23214-92-8 31703
46
Gabapentin Approved, Investigational Phase 3 60142-96-3 3446
47
gamma-Aminobutyric acid Approved, Investigational Phase 3 56-12-2 119
48
Triamcinolone Approved, Vet_approved Phase 3 124-94-7 31307
49
Dacarbazine Approved, Investigational Phase 3 4342-03-4 5351166
50
Procarbazine Approved, Investigational Phase 3 671-16-9 4915

Interventional clinical trials:

(show top 50) (show all 200)
# Name Status NCT ID Phase Drugs
1 Filgrastim for Premature Ovarian Insufficiency Unknown status NCT02783937 Phase 4 Saline
2 Effects of ADSC Therapy in Women With POF Unknown status NCT01853501 Phase 4
3 Evaluation of Physiologic and Standard Sex Steroid Replacement Regimens in Women With Premature Ovarian Failure Completed NCT00732693 Phase 4 Ethinylestradiol / Norethisterone;Estradiol / Progesterone
4 Flexible GnRH Antagonist vs Flare up GnRH Agonist Protocol in Poor Responders Completed NCT00417066 Phase 4 Ganirelix 0.25mg (Orgalutran, Organon, The Netherlands);Arvekap 0.1mg (Triptorelin, Ipsen, France)
5 Estrogen Dosing in Turner Syndrome: Pharmacology and Metabolism Completed NCT00837616 Phase 4 17 B estradiol orally;17 B estradiol
6 Long-Term Growth and Skeletal Effects of Early Growth Hormone Treatment in Turner Syndrome Completed NCT00266656 Phase 4 Humatrope
7 Defining the Optimal Hormonal Replacement Therapy in Turner Syndrome Completed NCT00134745 Phase 4 estradiol
8 Growth Response in Girls With Turner Syndrome Completed NCT01734486 Phase 4 somatropin;somatropin
9 Safety of Somatropin and Induction of Puberty With 17-beta-oestradiol in Girls With Turner Syndrome Completed NCT01518062 Phase 4 somatropin;somatropin;somatropin;oestrogen
10 Growth Hormone Treatment for the Prevention of Short Stature in Young Girls With Turner Syndrome Before the Age of 4 Years Completed NCT01066052 Phase 4 r-hGH
11 First Year Growth Response Associated Genetic Markers Validation Phase IV Open-label Study in Growth Hormone Deficient and Turner Syndrome Pre-pubertal Children: the PREDICT Pharmacogenetics Validation Study Completed NCT01419249 Phase 4
12 Predictive Markers in Growth Hormone Deficiency (GHD) and Turner Syndrome (TS) Children Treated With SAIZEN® Completed NCT00256126 Phase 4 Saizen;Saizen
13 Evaluation of the Ease of Use, Preference, and Safety of EutropinPen Inj. Completed NCT03015909 Phase 4 Somatropin
14 Norditropin NordiFlex® Device Compared to the Device Previously Used by Patients or Parents Completed NCT01245374 Phase 4
15 IMProving Executive Function Study Recruiting NCT03187353 Phase 4 Lisdexamfetamine;Placebo oral capsule
16 Autologous Bone Marrow Stem Cell Ovarian Transplantation to Restore Ovarian Function in Premature Ovarian Failure Not yet recruiting NCT03535480 Phase 4 G-CSF
17 Effect of Cetrorelex Acetate on Ovarian Function in Women Undergoing Chemotherapy Withdrawn NCT00507780 Phase 4 GnRH antagonist
18 Goserelin in Preventing Early Menopause in Premenopausal Women Undergoing Chemotherapy for Stage I, Stage II, or Stage III Breast Cancer Completed NCT00427245 Phase 3 cyclophosphamide;goserelin acetate
19 Triptorelin in Preventing Early Menopause in Premenopausal Women Who Are Receiving Chemotherapy for Stage I, Stage II, or Stage III Breast Cancer That Has Been Removed By Surgery Completed NCT00311636 Phase 3 cyclophosphamide;docetaxel;doxorubicin hydrochloride;epirubicin hydrochloride;fluorouracil;methotrexate;paclitaxel;triptorelin
20 Efficiency of Gonadotropin-releasing Hormone (GnRH) Agonist in Preventing Chemotherapy Induced Ovarian Failure Completed NCT01160315 Phase 2, Phase 3 Triptorelin;Norethisterone acetate
21 S0230 Goserelin in Preventing Ovarian Failure in Women Receiving Chemotherapy for Breast Cancer Completed NCT00068601 Phase 3 cyclophosphamide;goserelin acetate
22 Pilot Study Comparing Hypnotherapy and Gabapentin for Hot Flashes. Completed NCT00711529 Phase 3 gabapentin
23 Estrogen Treatment (Oral vs. Patches) in Turner Syndrome Completed NCT00140998 Phase 3 17 beta estradiol
24 Administration During Chemotherapy to Reduce Ovarian Failure Following Chemotherapy in Early Stage, Hormone-Receptor Negative Breast Cancer Completed NCT01530607 Phase 3 Standard cyclophosphamide;Goserelin (Zoladex)
25 An Open-Label, Multi-centre, Phase III Study of Local Tolerability of ZOMACTON 10MG Completed NCT00250250 Phase 3 ZOMACTON
26 Combination Chemotherapy in Treating Young Patients With Hodgkin's Lymphoma Completed NCT00433459 Phase 3 cyclophosphamide;dacarbazine;prednisolone;prednisone;procarbazine hydrochloride;vincristine sulfate
27 A Clinical Study to Assess the Efficacy and Safety of DA-3002 Completed NCT01813630 Phase 3 DA-3002;Genotropin®
28 The Effect of Growth Hormone in Very Young Girls With Turner Syndrome Completed NCT00406926 Phase 3 Somatropin
29 Somatropin Treatment to Final Height in Turner Syndrome Completed NCT00191113 Phase 3 Somatropin;Ethinyl estradiol;Medroxyprogesterone acetate
30 The Effect of Androgen and Growth Hormone on Height and Learning in Girls With Turner Syndrome Completed NCT00029159 Phase 3 estrogen;androgen
31 Induction of Puberty With 17-beta Estradiol in Girls With Turner Syndrome Completed NCT01710696 Phase 3 17-beta estradiol;17-beta estradiol
32 Use of Somatropin in Turner Syndrome Completed NCT01518036 Phase 3 somatropin;somatropin
33 Evaluating Acceptance of New Liquid Somatropin Formulation in Children With Growth Hormone Deficiency Completed NCT01563926 Phase 3 somatropin
34 Study to Define Optimal IGF-1 Monitoring in Children Treated With NutropinAq Completed NCT00234533 Phase 3 Somatropin (rDNA origin)
35 Hormone Replacement for Premature Ovarian Insufficiency Recruiting NCT02922348 Phase 3 Hormone Replacement Therapy;Combined Oral Contraceptives
36 Primary Ovarian Insufficiency: Phenotype and Optimal Treatment Recruiting NCT03568708 Phase 3 Transdermal Estrogen
37 Dehydroepiandrosterone (DHEA) Treatment and Premature Ovarian Failure (POF) Terminated NCT00948857 Phase 2, Phase 3
38 Effect of Exercise and Phytoestrogen on Bone, Metabolic Syndrome Criteria and Complaints of the Early Menopause Terminated NCT00663104 Phase 3
39 Study of Oral Dehydroepiandrosterone(DHEA) to Treat Previously Unexplained Infertility Terminated NCT00650754 Phase 2, Phase 3
40 Goserelin Acetate Study for Ovarian Function in Patients With Primary Breast Cancer Terminated NCT00429403 Phase 3 Goserelin
41 Stem Cell Therapy Combined Hormone Replacement Therapy in Patients With Premature Ovarian Failure Unknown status NCT01742533 Phase 1, Phase 2 Hormone Replacement Therapy
42 Autologous Mesenchymal Stem Cells Transplantation In Women With Premature Ovarian Failure Unknown status NCT02062931 Phase 1, Phase 2
43 Autologous Stem Cells Transplantation in Patients With Idiopathic and Drug Induced Premature Ovarian Failure Unknown status NCT02043743 Phase 1, Phase 2
44 Human Umbilical Cord Mesenchymal Stem Cells (HUC-MSCs) Transplantation in Women With Primary Ovarian Insufficiency (POI) Unknown status NCT03033277 Phase 1, Phase 2
45 Transplantation of HUC-MSCs With Injectable Collagen Scaffold for POF Unknown status NCT02644447 Phase 1, Phase 2
46 Chinese Medicine(Hu Yang Yang Kun Formula) for Primary Ovarian Insufficiency Completed NCT02794948 Phase 1, Phase 2
47 Pregnancy After Stem Cell Transplantation in Premature Ovarian Failure Completed NCT02151890 Phase 1, Phase 2
48 "It is a Real" The First Baby Of Autologous Stem Cell Therapy in Premature Ovarian Failure Completed NCT02372474 Phase 1, Phase 2
49 Hormone Replacement in Young Women With Premature Ovarian Failure Completed NCT00001951 Phase 2 TMTDS
50 GnRH Analogue for Ovarian Function Preservation in Hematopoietic Stem Cell Transplantation Patients Completed NCT00429494 Phase 2 Leuprolide Acetate

Search NIH Clinical Center for Premature Menopause

Inferred drug relations via UMLS 73 / NDF-RT 51 :


Cochrane evidence based reviews: menopause, premature

Genetic Tests for Premature Menopause

Anatomical Context for Premature Menopause

MalaCards organs/tissues related to Premature Menopause:

41
Bone, Ovary, Testes, Thyroid, Breast, T Cells

Publications for Premature Menopause

Articles related to Premature Menopause:

(show top 50) (show all 125)
# Title Authors Year
1
Cholesterol profile in women with premature menopause after risk reducing salpingo-oophorectomy. ( 29881922 )
2018
2
Nonsurgical premature menopause and reproductive implications in survivors of childhood cancer: A report from the Childhood Cancer Survivor Study. ( 29338081 )
2018
3
A High-risk Haplotype for Premature Menopause in Childhood Cancer Survivors Exposed to Gonadotoxic Therapy. ( 29432556 )
2018
4
Identifying Biomarkers for Risk of Premature Menopause Among Childhood Cancer Survivors May Lead to Targeted Interventions and Wellness Strategies. ( 29432587 )
2018
5
Ovarian ablation for premenopausal breast cancer: A review of treatment considerations and the impact of premature menopause. ( 28288389 )
2017
6
Prevalence and Determinants of Premature Menopause among Indian Women: Issues and Challenges Ahead. ( 28340231 )
2017
7
Dealing with premature menopause in women at high-risk for hereditary genital and breast cancer. ( 26928421 )
2016
8
Managing premature menopause and sexual dysfunction. ( 26155020 )
2015
9
Hormone treatment may help prevent premature menopause in cancer patients. ( 26702070 )
2015
10
Spanish consensus on premature menopause. ( 25578643 )
2015
11
Prevention of Premature Menopause and Preservation of Fertility in Young Cancer Survivors: Hopeful Though Modest Long-term Results. ( 26720024 )
2015
12
Autosomal Translocation Patient Who Experienced Premature Menopause: A Case Report. ( 26356509 )
2015
13
Premature Menopause. ( 26316242 )
2015
14
Impact of a premature menopause on cognitive function in later life. ( 24802975 )
2014
15
Premature menopause and risk of neurological disease: basic mechanisms and clinical implications. ( 24462786 )
2014
16
Symptoms, health behavior and understanding of menopause therapy in women with premature menopause. ( 24742007 )
2014
17
Risk of premature menopause after treatment for Hodgkin's lymphoma. ( 25139687 )
2014
18
An interpretive description of chemotherapy-induced premature menopause among Latinas with breast cancer. ( 25158665 )
2014
19
Premature menopause - Meeting the needs. ( 24879744 )
2014
20
Risk of premature menopause after treatment for Hodgkin's lymphoma. ( 25139688 )
2014
21
Premature menopause. ( 23634337 )
2013
22
Frequency of premature menopause in women who carry a BRCA1 or BRCA2 mutation. ( 23414920 )
2013
23
Premature menopause in young breast cancer: effects on quality of life and treatment interventions. ( 23819028 )
2013
24
Psychosocial adjustment in women with premature menopause: a cross-sectional survey. ( 22335389 )
2012
25
Premature menopause or early menopause and risk of ischemic stroke. ( 21993082 )
2012
26
Ovarian suppression for prevention of premature menopause and infertility: empty promise or effective therapy? ( 22231046 )
2012
27
A nationwide study on reproductive function, ovarian reserve, and risk of premature menopause in female survivors of childhood cancer: design and methodological challenges. ( 22917040 )
2012
28
Hormone replacement therapy and women with premature menopause--a cancer survivorship issue. ( 21561765 )
2011
29
Premature menopause and severity of coronary artery disease. ( 22279478 )
2011
30
Premature menopause: a comprehensive understanding of psychosocial aspects. ( 21854296 )
2011
31
Premature menopause linked to CVD and osteoporosis. ( 20408329 )
2010
32
Menopause and sexuality: key issues in premature menopause and beyond. ( 20840281 )
2010
33
Premature menopause or early menopause: long-term health consequences. ( 19733988 )
2010
34
Premature menopause is associated with increased risk of cerebral infarction in Japanese women. ( 20042893 )
2010
35
Successful pregnancy with frozen embryo transfer into a gestational carrier from eggs obtained from a woman in premature menopause. ( 19860356 )
2009
36
Premature menopause increases cardiovascular risk. ( 19811237 )
2009
37
Premature menopause: exploring the experience through online communication. ( 19298304 )
2009
38
The concept and treatment methodology for inducing ovulation in women in apparent premature menopause. ( 19688943 )
2009
39
HRT in premature menopause. ( 18796482 )
2008
40
Treatment-related risk factors for premature menopause following Hodgkin lymphoma. ( 17890454 )
2008
41
Ovulation induction and pregnancy in a woman with premature menopause following gonadotropin suppression with the gonadotropin releasing hormone antagonist, cetrorelix--a case report. ( 18404830 )
2008
42
Suspected premature menopause. ( 18403549 )
2008
43
Premature menopause: Hormone replacement therapy is indeed indicated. ( 18497386 )
2008
44
Premature menopause: Article's recommendation of HRT is highly questionable. ( 18467384 )
2008
45
"Coming to grips" with chemotherapy-induced premature menopause. ( 18389434 )
2008
46
Treatment of premature menopause in breast cancer patients. ( 17685250 )
2007
47
Effect of premature menopause on sexuality. ( 19804022 )
2007
48
Management of premature menopause. ( 17448268 )
2007
49
Do survivors of childhood cancer have increased incidence of premature menopause? ( 17259929 )
2007
50
Premature menopause in patients with BRCA1 gene mutation. ( 16773440 )
2006

Variations for Premature Menopause

Expression for Premature Menopause

Search GEO for disease gene expression data for Premature Menopause.

Pathways for Premature Menopause

Pathways related to Premature Menopause according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1 11.8 BRCA1 BRCA2 POLG
2
Show member pathways
11.6 BRCA1 BRCA2 SYCE1
3 9.4 TG TPO

GO Terms for Premature Menopause

Cellular components related to Premature Menopause according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 lateral element GO:0000800 8.62 BRCA1 BRCA2

Biological processes related to Premature Menopause according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cell cycle GO:0007049 9.62 BRCA1 BRCA2 SGO2 SYCE1
2 double-strand break repair GO:0006302 9.43 BRCA1 BRCA2
3 aging GO:0007568 9.43 AMH GNRH1 POLG
4 intrinsic apoptotic signaling pathway in response to DNA damage GO:0008630 9.4 BRCA1 BRCA2
5 response to gamma radiation GO:0010332 9.37 BRCA2 POLG
6 DNA damage response, signal transduction by p53 class mediator resulting in transcription of p21 class mediator GO:0006978 9.16 BRCA1 BRCA2
7 hormone biosynthetic process GO:0042446 8.96 TG TPO
8 chordate embryonic development GO:0043009 8.62 BRCA1 BRCA2

Molecular functions related to Premature Menopause according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 hormone activity GO:0005179 8.8 AMH GNRH1 TG

Sources for Premature Menopause

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....